| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.018 | 0.5 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |